Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.4.0.3
Commitments and Contingencies - Additional Information (Detail)
3 Months Ended 12 Months Ended
Mar. 31, 2016
USD ($)
Milestone
Dec. 31, 2013
shares
UFRF License Agreement [Member]    
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 5.00%  
Company's obligation to pay from all revenue received from sublicenses 22.00%  
One-time commercialization fee monthly amount for calculation $ 5,000  
Post-commercialization minimum royalty payments 50,000  
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount $ 2,000,000  
One-time additional payment to UFRF as a percentage of total royalties due to UFRF 10.00%  
Minimum annual maintenance payment on license agreement $ 10,000  
Quarterly maintenance payment to UFRF under installment plan $ 2,500  
Termination notice period 90 days  
Texas A and M University License [Member]    
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 5.00%  
Post-commercialization minimum royalty payments $ 100,000  
Initial payment to Texas A&M 5,000  
Minimum consideration for the continuation of the license agreement 15,000  
Annual maintenance payment under licensing agreement with Texas A&M $ 100,000  
Number of milestones achieved | Milestone 0  
Texas A and M University License [Member] | Phase 2 Clinical Trial [Member    
Commitment And Contingencies [Line Items]    
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2019  
Milestone payment under licensing agreement $ 100,000  
Texas A and M University License [Member] | Phase 3 Clinical Trial [Member]    
Commitment And Contingencies [Line Items]    
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2022  
Milestone payment under licensing agreement $ 150,000  
Texas A and M University License [Member] | Phase 1 Clinical Trial [Member]    
Commitment And Contingencies [Line Items]    
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2016  
Milestone payment under licensing agreement $ 50,000  
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]    
Commitment And Contingencies [Line Items]    
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2025  
Milestone payment under licensing agreement $ 400,000  
Texas A and M University License [Member] | Minimum [Member]    
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 2.00%  
Lantibiotic ECC [Member]    
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 25.00%  
Company's obligation to pay from all revenue received from sublicenses 50.00%  
Number of milestones achieved | Milestone 0  
Number of shares issued | shares   4,392,425
Maximum percentage of primary investment securities to investment of shares issued 10.00%  
Lantibiotic ECC [Member] | Investigational New Drug Application [Member]    
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 1.00%  
Lantibiotic ECC [Member] | Phase 2 Clinical Trial [Member    
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 1.50%  
Lantibiotic ECC [Member] | Phase 3 Clinical Trial [Member]    
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 2.00%  
Lantibiotic ECC [Member] | New Drug Application or Biologics License Application [Member]    
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 2.50%  
Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member]    
Commitment And Contingencies [Line Items]    
Percentage of number of shares of common stock equal to Base Shares 3.00%  
Oral Mucositis ECC [Member]    
Commitment And Contingencies [Line Items]    
Company's obligation to pay from percentage of selling price of product 12.00%  
Company's obligation to pay from all revenue received from sublicenses 50.00%  
Number of milestones achieved | Milestone 0  
Oral Mucositis ECC [Member] | Phase II Milestone Event [Member]    
Commitment And Contingencies [Line Items]    
Milestone payment under licensing agreement $ 2,000,000  
Milestone measurement period 30 days  
Oral Mucositis ECC [Member] | Phase 2b/3 Milestone Event [Member]    
Commitment And Contingencies [Line Items]    
Milestone payment under licensing agreement $ 5,000,000  
Milestone measurement period 30 days  
Oral Mucositis ECC [Member] | Regulatory Approval Application Milestone Event [Member]    
Commitment And Contingencies [Line Items]    
Milestone payment under licensing agreement $ 5,000,000  
Milestone measurement period 30 days  
Oral Mucositis ECC [Member] | Approval Milestone Event [Member]    
Commitment And Contingencies [Line Items]    
Milestone payment under licensing agreement $ 10,000,000  
Milestone measurement period 30 days  
Oral Mucositis ECC [Member] | New Indication Milestone Event [Member]    
Commitment And Contingencies [Line Items]    
Milestone payment under licensing agreement $ 5,000,000  
Milestone measurement period 30 days  
Oral Mucositis ECC [Member] | New Product Milestone Event [Member]    
Commitment And Contingencies [Line Items]    
Milestone payment under licensing agreement $ 5,000,000  
Milestone measurement period 30 days  
Oral Mucositis ECC [Member] | Maximum [Member]    
Commitment And Contingencies [Line Items]    
Maturity of interest bearing promissory note 12 months